Myeloma XI long-term follow-up: Graham Jackson update
Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, discusses…
Related Articles
Post-EHA 2025 AML Highlights | VJHemOnc
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our…
BTK degraders in CLL: mechanism of action, patient responses, and a look to the future
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, comments on the potential of proteolysis-targeting chimeras (PROTACs), also known as degraders, in the treatment of…
Experience with the RESTART protocol: integrating radiotherapy into the peri-CAR-T setting for LBCL
Andrea Kuhnl, MD, King’s College Hospital, London, UK, comments on the UK experience with the RESTART protocol, a prospective study that integrates radiotherapy into the…
Hot topics in AML from EHA 2025: menin inhibitors, adjusting venetoclax dose, & maintenance therapy
Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, comments on the hottest topics in acute myeloid leukemia (AML) at EHA 2025. She highlights…
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, shares insights into the data from cohort G of the MagnetisMM-6 trial (NCT05623020),…
Update on the KOMET-001 trial: ziftomenib in NPM1-mutant AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, presents the updated results of the pivotal Phase II KOMET-001 study (NCT04067336), which examined the…
Results of the BEXMAB study: efficacy of bexmarilimab plus azacitidine in MDS
Mika Kontro, MD, PhD, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, presents the results of the BEXMAB study (NCT05428969), a Phase I/II trial investigating…
Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain
In this episode of the VJHemOnc podcast, we are joined by Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, a…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…